John Wiley & Sons, Inc. (WLY) Cash Flow Statement

John Wiley & Sons, Inc. (WLY) generated $290.3M of operating cash flow over the twelve months to 2026-07-31, spent $64.7M on capital expenditure and had free cash flow of $225.6M, according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-07-31 · read by EquiReason

WLYJohn Wiley & Sons, Inc.Follow WLY — free

Publishing · Communication Services

—

Price chart with a free account

Market cap: 2.7B
P/E TTM: 14.5
Dividend yield: 2.6%
52-week: —
Next earnings: 2 Dec, in 39 days

Line	FY2011 Apr 11	FY2012 Apr 12	FY2013 Apr 13	FY2014 Apr 14	FY2015 Apr 15	FY2016 Apr 16	FY2017 Apr 17	FY2018 Apr 18	FY2019 Apr 19	FY2020 Apr 20	FY2021 Apr 21	FY2022 Apr 22	FY2023 Apr 23	FY2024 Apr 24	FY2025 Apr 25	FY2026 Apr 26	TTM Jul 26
Operating cash flow	0.38	0.38	0.34	0.35	0.36	0.35	0.31	0.38	0.25	0.29	0.36	0.34	0.28	0.21	0.20	0.26	0.29
Capital expenditure	0.05	0.07	0.06	0.06	0.07	0.09	0.11	0.11	0.08	0.09	0.08	0.12	0.10	0.09	0.08	0.07	-0.06
Free cash flow	0.32	0.31	0.28	0.29	0.29	0.26	0.21	0.27	0.17	0.20	0.28	0.22	0.17	0.11	0.13	0.20	0.23
Dividends paid	0.04	0.05	0.06	0.06	0.07	0.07	0.07	0.07	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.07	—
Share repurchases	0.03	0.09	0.07	0.06	0.06	0.07	0.05	0.04	0.06	0.05	0.02	0.03	0.04	0.05	0.06	0.10	—
Stock-based compensation	0.02	0.02	0.01	0.01	0.01	0.02	0.02	0.01	0.02	0.02	0.02	0.03	0.03	0.02	0.02	0.02	—

USD billions · SEC XBRL

John Wiley & Sons, Inc. — questions

What is John Wiley & Sons, Inc.'s operating cash flow?: $290.3M over the twelve months to 2026-07-31.
How much does John Wiley & Sons, Inc. spend on capital expenditure?: $64.7M over the twelve months to 2026-07-31.
What is John Wiley & Sons, Inc.'s free cash flow?: $225.6M over the twelve months to 2026-07-31: operating cash flow minus capital expenditure.

Every figure on this page comes from John Wiley & Sons, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.